Skip to main content
Evidence Snapshot

Multidrug resistance-associated protein 1

CHEMBL3004 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:46Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3004
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Multidrug resistance-associated protein 1 as ChEMBL target CHEMBL3004, mapped to UniProt P33527. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Multidrug resistance-associated protein 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3004
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P33527
Multidrug resistance-associated protein 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Multidrug resistance-associated protein 1 matters

As of 2026-09-13

Multidrug resistance-associated protein 1 is reviewed as Multidrug resistance-associated protein 1 (UniProt P33527); the current evidence base includes 18 approved drugs, 1730 compounds, and 445 assays, with lead potency reaching pChEMBL 8.8.

Protein context
Multidrug resistance-associated protein 1

Multidrug resistance-associated protein 1 Sequence length is 1531 aa.

Review this target as Multidrug resistance-associated protein 1, mapped to UniProt P33527. Sequence length is 1531 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P33527 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 1730 compounds, and 445 assays for this target. The dominant activity type is IC50. CHEMBL58 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL58 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Multidrug resistance-associated protein 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P33527, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1730
Total Compounds
445
Total Assays
18
Approved Drugs
IC50: 716.0, KI: 40.0, EC50: 323.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL58
 8.8 IC50 Approved
No preferred name
CHEMBL28629
 8.0 IC50 —
No preferred name
CHEMBL281496
 8.0 IC50 —
No preferred name
CHEMBL26779
 8.0 IC50 —
No preferred name
CHEMBL25903
 7.9 IC50 —

Approved Drugs

Structure Compound First Approval
MITOXANTRONE
CHEMBL58
 1987
VERAPAMIL
CHEMBL6966
 1981
DAUNORUBICIN
CHEMBL178
 1979
ESTRONE SULFURIC ACID
CHEMBL494753
 1977
BENZBROMARONE
CHEMBL388590
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:46Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3004